Centenial Surgic

Why is Centenial Surgical Suture Ltd falling/rising?

As of 13-Aug, Centenial Surgical Suture Ltd's stock price is rising to 86.15, reflecting a 5.0% increase. Despite some erratic trading and a drop in delivery volume, the stock's current price exceeds its moving averages, indicating a short-term positive trend.

As of 13-Aug, Centenial Surgical Suture Ltd's stock price is rising, currently at 86.15, which reflects a change of 4.1 or 5.0% increase. This upward movement is supported by several factors. The stock has outperformed its sector by 5% today and opened with a gain of 5%. It also reached an intraday high of Rs 86.15, indicating strong performance within the trading day. <BR><BR>Additionally, the stock's performance over the past week shows a gain of 5.54%, contrasting with the Sensex, which declined by 1.11%. However, it is important to note that the stock has experienced erratic trading, not trading on 2 out of the last 20 days, and there has been a significant drop in delivery volume by 67.35% against the 5-day average, suggesting a decline in investor participation. <BR><BR>Despite these concerns, the stock's current price is higher than its 5-day, 20-day, and 50-day moving averages, which can indicate a short-term positive trend. Overall, the combination of today's strong performance and recent gains contributes to the rising stock price of Centenial Surgical Suture Ltd.

Which are the latest news on Centenial Surgic?

Who are in the management team of Centenial Surgic?

The management team of Centenial Surgic includes Vijay Majrekar (Chairman/Executive Director), Anuradha Kashikar (Executive Director/Whole Time Director), Devraj T Poojary (Executive Director/Whole Time Director), and four Independent Non-Executive Directors: B S Limaye, Sunil C Modi, Jagadish B Shetty, and N M Vora.

The management team of Centenial Surgic includes the following members:<BR><BR>1. **Vijay Majrekar** - Chairman / Executive Director<BR>2. **Anuradha Kashikar** - Executive Director / Whole Time Director<BR>3. **Devraj T Poojary** - Executive Director & Whole Time Director<BR>4. **B S Limaye** - Independent Non-Executive Director<BR>5. **Sunil C Modi** - Independent Non-Executive Director<BR>6. **Jagadish B Shetty** - Independent Non-Executive Director<BR>7. **N M Vora** - Independent Non-Executive Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Centenial Surgic do?

Centenial Surgical Suture Ltd manufactures and sells surgical sutures and is classified as a micro-cap company with a market cap of INR 30 Cr. As of March 2026, it reported net sales of 13 Cr and a net loss of 2 Cr.

Overview: <BR>Centenial Surgical Suture Ltd is engaged in the manufacture and sale of surgical sutures within the healthcare services industry, classified as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1995, Centenial Surgical Suture has maintained its focus on surgical sutures. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 13 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 30 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.37 <BR>Return on Equity: -7.74% <BR>Price to Book: 1.05<BR><BR>Contact Details: <BR>Address: Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401 <BR>Tel: 91-2524-222905/222906 <BR>Email: admin@centenialindia.com <BR>Website: http://www.centenialindia.com

Who are the peers of the Centenial Surgic?

Centenial Surgic's peers include N G Industries, Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, and others. In terms of performance, Centenial Surgic has a 1-year return of -44.56%, better than Bandaram Pharma's -51.19% but worse than Chennai Meena's 20.57%.

Peers: The peers of Centenial Surgic are N G Industries, Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, Tejnaksh Health., Chennai Meena, Samsrita Labs, Adeshwar Meditex, Sunrest Lifescie, and Galaxy Medicare.<BR><BR>Quality Snapshot: Good management risk is observed at N G Industries and Sunrest Lifescie, while Below Average management risk is found at Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, Tejnaksh Health., Adeshwar Meditex, and Galaxy Medicare, and the rest. Excellent growth is noted at Sunrest Lifescie, while Good growth is seen at Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, and the rest, and Below Average growth is present at Centenial Surgic, Tejnaksh Health., and Adeshwar Meditex. Good capital structure is found at N G Industries, Deccan Healthcar, GKB Ophthalmics, and Sunrest Lifescie, while Average capital structure is observed at Centenial Surgic and Adeshwar Meditex, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chennai Meena at 20.57%, while the peer with the lowest is Bandaram Pharma at -51.19%. Centenial Surgic's 1-year return of -44.56% is better than Bandaram Pharma's but worse than Chennai Meena's. Additionally, several peers, including Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, Tejnaksh Health., Samsrita Labs, and Adeshwar Meditex, have negative six-month returns.

When is the next results date for Centenial Surgical Suture Ltd?

The next results date for Centenial Surgical Suture Ltd is August 14, 2026.

The next results date for Centenial Surgical Suture Ltd is scheduled for August 14, 2026.

How big is Centenial Surgic?

As of 10th June, Centenial Surgical Suture Ltd has a market capitalization of 30.00 Cr and reported net sales of 53.84 Cr with a net loss of 2.21 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Centenial Surgical Suture Ltd has a market capitalization of 30.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 53.84 Cr. The sum of Net Profit for the latest 4 quarters shows a loss of 2.21 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 30.75 Cr, and Total Assets amount to 84.55 Cr.

Should I buy, sell or hold Centenial Surgical Suture Ltd?

Are Centenial Surgical Suture Ltd latest results good or bad?

Centenial Surgical Suture Ltd's latest results are negative, showing a net loss of ₹2.31 crores in Q4 FY26, a 95.8% decline year-over-year, with revenue dropping 15.34% from the previous quarter. The company's stock has also underperformed, falling 37.76% over the past year.

Centenial Surgical Suture Ltd's latest results indicate a troubling performance. In the fourth quarter of FY26, the company reported a net loss of ₹2.31 crores, which is a significant decline of 95.8% year-over-year. Revenue also fell to ₹12.58 crores, down 15.34% from the previous quarter and 5.48% compared to the same quarter last year. This marks the lowest quarterly revenue for the fiscal year.<BR><BR>The operating margin has dropped to 7.39%, down from 15.55% in the same quarter last year, reflecting severe operational challenges. Additionally, interest costs surged by 531% quarter-over-quarter, further exacerbating the financial strain.<BR><BR>Overall, the company's stock has underperformed significantly, declining 37.76% over the past year, contrasting sharply with the broader Healthcare Services sector, which has seen an 18.74% increase. These results suggest that Centenial Surgical Suture is facing substantial operational and financial difficulties, making the latest results decidedly negative.

How has been the historical performance of Centenial Surgic?

Centenial Surgic's historical performance shows fluctuating net sales, increasing from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, but it reported a loss with a profit after tax of -1.46 Cr in Mar'25, despite improved operating efficiency and cash flow from operations. Total liabilities and assets rose to 84.55 Cr in Mar'25, indicating financial challenges.

Answer:<BR>The historical performance of Centenial Surgic shows a fluctuating trend in net sales and profitability over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Centenial Surgic's net sales increased from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 53.52 Cr in Mar'25 from 51.19 Cr in Mar'24. However, the company's total expenditure, excluding depreciation, increased slightly to 47.26 Cr in Mar'25 from 46.18 Cr in Mar'24. Operating profit, excluding other income, improved to 6.26 Cr in Mar'25 from 5.01 Cr in Mar'24, indicating better operational efficiency. Despite this, the company reported a profit before tax of -1.62 Cr in Mar'25, a decline from a profit of 1.27 Cr in Mar'24, leading to a profit after tax of -1.46 Cr in Mar'25 compared to 1.13 Cr in Mar'24. The total liabilities rose to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24, while total assets also increased to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24. The cash flow from operating activities improved to 17.00 Cr in Mar'25 from 6.00 Cr in Mar'24, but cash flow from investing activities was negative at -11.00 Cr. Overall, the company faced challenges in profitability despite an increase in sales and operating income.

Is Centenial Surgic overvalued or undervalued?

As of May 30, 2025, Centenial Surgic is considered very attractive and undervalued with a PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68, especially when compared to competitors like Max Healthcare and Apollo Hospitals, while also boasting a strong 1-year stock return of 40.95%.

As of 30 May 2025, the valuation grade for Centenial Surgic has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company appears to be undervalued, especially when considering its current PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68. These figures suggest that despite the negative earnings reflected in the PE ratio, the company's valuation metrics are more favorable compared to its peers.<BR><BR>In comparison to notable competitors, Max Healthcare has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals shows a PE of 69.03 and an EV to EBITDA of 34.71. This stark contrast highlights Centenial Surgic's attractive valuation relative to its peers in the healthcare services industry. Additionally, the company's strong stock performance, with a 1-year return of 40.95% compared to the Sensex's 7.62%, reinforces the narrative that it is currently undervalued in the market.

What is the technical trend for Centenial Surgic?

As of June 6, 2025, Centennial Surgic's technical trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly indicators and short-term bearishness in daily moving averages.

As of 6 June 2025, the technical trend for Centenial Surgic has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. The Dow Theory also shows a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from the monthly indicators.

Who are the top shareholders of the Centenial Surgic?

The top shareholders of Centenial Surgic are Vijay Kalidas Majrekar with 22.62%, and Kartik Shyam Kingar with 16.7%. Individual investors own a combined 50.29%, with no institutional holdings reported.

The top shareholders of Centenial Surgic include Vijay Kalidas Majrekar, who holds the highest promoter stake at 22.62%. The highest public shareholder is Kartik Shyam Kingar, with a holding of 16.7%. Additionally, individual investors collectively own 50.29% of the company. There are no institutional holdings from mutual funds or foreign institutional investors.

Has Centenial Surgic declared dividend?

No Dividend History Available